Publikationen, an denen er mitarbeitet Alberto Ocaña (10)

2020

  1. Inhibition of the mitotic kinase PLK1 overcomes therapeutic resistance to BET inhibitors in triple negative breast cancer

    Cancer Letters, Vol. 491, pp. 50-59

2019

  1. A Transcriptomic Immunologic Signature Predicts Favorable Outcome in Neoadjuvant Chemotherapy Treated Triple Negative Breast Tumors

    Frontiers in Immunology, Vol. 10

  2. Activity of BET-proteolysis targeting chimeric (PROTAC) compounds in triple negative breast cancer

    Journal of Experimental and Clinical Cancer Research, Vol. 38, Núm. 1

2016

  1. Neuregulin expression in solid tumors: Prognostic value and predictive role to anti-HER3 therapies

    Oncotarget, Vol. 7, Núm. 29, pp. 45042-45051

  2. Targeting the EGF/HER ligand-receptor system in cancer

    Current Pharmaceutical Design, Vol. 22, Núm. 39, pp. 5887-5898

2014

  1. Active kinase profiling, genetic and pharmacological data define mTOR as an important common target in triple-negative breast cancer

    Oncogene, Vol. 33, Núm. 2, pp. 148-156

  2. Therapeutic potential of ERK5 targeting in triple negative breast cancer

    Oncotarget, Vol. 5, Núm. 22, pp. 11308-11318

2009

  1. Expression of Erk5 in early stage breast cancer and association with disease free survival identifies this kinase as potential therapeutic target

    PLoS ONE, Vol. 4, Núm. 5

2008

  1. Synergic antitumoral effect of an IGF-IR inhibitor and trastuzumab on HER2-overexpressing breast cancer cells

    Annals of Oncology, Vol. 19, Núm. 11, pp. 1860-1869

2007

  1. Neuregulin expression modulates clinical response to trastuzumab in patients with metastatic breast cancer

    Journal of Clinical Oncology, Vol. 25, Núm. 19, pp. 2656-2663